Target intelligence / Profile preview

PTB domain-containing engulfment adapter protein 1 (GULP1)

Target
GULP1
Molecular classification
Other (Adapter protein; contains phosphotyrosine-binding (PTB) domain)
01

Overview

PTB domain-containing engulfment adapter protein 1 (GULP1) is a highly conserved cytoplasmic adapter protein essential for the phagocytosis of apoptotic cells by phagocytes[1][7]. It acts by binding to NPXY motifs found in the cytoplasmic tails of various engulfment receptors via its phosphotyrosine-binding (PTB) domain, thereby linking these receptors (such as stabilin-1, stabilin-2, Jedi-1, and low-density lipoprotein receptor family members) to intracellular signaling pathways regulating actin cytoskeletal remodeling and endocytosis[1][8]. GULP1 is involved not only in cellular clearance but also in modulating glycosphingolipid and cholesterol transport, endosomal trafficking, and regulating amyloid precursor protein (APP) processing, influencing amyloid-β generation[1][3][5][7]. Differential expression and function of GULP1 have been implicated in neurodegenerative diseases (e.g., Alzheimer’s disease), various cancers as a potential biomarker and modulator of tumor immune response, and rare metabolic disorders[2][5][7]. While recognized as biologically relevant to disease processes, GULP1 is not currently identified as a direct therapeutic target or druggable enzyme, receptor, or transporter.

Other names
GULP1GULPCED-6CED6Cell death protein 6 homologPTB domain adapter protein CED-6Engulfment adaptor PTB domain containing 1Protein GULP
02

Biological functions

Phagocytosis of apoptotic cellsAdapter protein for signaling complexesEndocytosisModulation of glycosphingolipid and cholesterol transportRegulation of cell death and downstream cytoskeletal remodelingInternalization and endosomal trafficking
03

Disease associations

Cancer (biomarker; tumor invasion, metastasis, proliferation, and prognosis)Neurodegenerative disease (Alzheimer's disease via amyloid precursor protein processing)Lysosomal storage disorders (e.g., Niemann-Pick disease, Type B)Thyroid dyshormonogenesis 4
04

Safety considerations

Modulation of GULP1-APP interaction may influence amyloid-β production, which is relevant in Alzheimer’s disease therapy but may have off-target effectsAberrant expression is linked to tumor progression and immune escape
05

Biomarkers

Prognostic biomarker in several cancers: pancreatic, glioma, melanoma, and othersBiomarker for immunotherapy response and chemotherapy resistance in select cancers

Beyond the preview

Go deeper on PTB domain-containing engulfment adapter protein 1 (GULP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTB domain-containing engulfment adapter protein 1 (GULP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call